Inato

What Inato does

Inato SAS is a Paris-based clinical trial technology company founded in 2016 that operates a two-sided marketplace connecting pharmaceutical sponsors with clinical research sites. The platform serves 25+ enterprise pharmaceutical companies (including Sanofi, Pfizer, Amgen, Lilly, AstraZeneca, and Kailera) and 6,000+ research sites across more than 50 countries, with the core value proposition centered on accelerating trial enrollment and improving patient diversity through better site selection and patient matching. The platform is organized into three integrated capabilities: early trial planning, AI Site Selection (drawing on verified data from 5,500+ sites, launched September 2025), and AI Patient Pre-Screening (launched January 2025). Underlying the AI features is a proprietary multimodal LLM pipeline that uses visual language models and reasoning models to interpret patient records without OCR, validated through a peer-reviewed paper in Nature Digital Medicine.

The technology stack integrates with the broader clinical trial ecosystem through partnerships with RealTime eClinical Solutions (combining TrialAlign site data, September 2025), CRIO (Partners Program, April 2025), and eClinPro (Site CTMS integration, April 2026). Documented integrations also include ClinicalTrials.gov and EHR systems. The business model is a quote-based enterprise B2B subscription, with direct field sales to pharmaceutical sponsors complemented by a self-serve marketplace for research sites. The company is ISO 27001 and HIPAA compliant and has raised approximately $35.5 million in total disclosed funding across seed (2017), Series A (2020, $14M led by Cathay Innovation and Obvious Ventures), and Series A2 (March 2023, $20M led by Cathay Innovation). The company has 51-100 employees and is led by Co-founder and CEO Kourosh Davarpanah alongside Co-founder and CSO Liz Beatty and Co-founder Philippe Ravaud.

Name

Inato

Legal name

Inato SAS

Website

https://inato.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

51–100 employees

Short description

Inato is a Paris-based AI-powered clinical trial platform connecting 25+ pharmaceutical sponsors with 6,000+ research sites across 50+ countries, offering AI site selection and AI patient pre-screening to accelerate enrollment and improve trial diversity.

Ownership category

akta.pro rank

Product category

Clinical Trial Technology

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Site & Investigator Platforms (Site Payments, Feasibility, Activation) (HLACAOAJ)

akta.pro secondary industry

Clinical Trial Site Operations & Study Coordination (HLAGACAE)

Keywords

• Clinical trial platform
• Patient pre-screening
• Site selection software
• Clinical trial enrollment
• Sponsor-site matching

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Platform Subscription / Marketplace Access: Inato operates a marketplace model where pharmaceutical sponsors pay for access to site data, site selection tools, and patient pre-screening capabilities. Research sites access the platform to find trial opportunities and use pre-screening tools. The platform serves as a two-sided marketplace connecting sponsors and sites.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels6 records

Core offering

Inato provides an AI-powered two-sided marketplace platform that connects pharmaceutical sponsors with clinical research sites. Its offering combines early trial planning, AI-driven site selection using verified data from 5,500+ sites, and AI patient pre-screening that automates chart review against protocol eligibility criteria, reducing manual review time by up to 90%. The platform serves 25+ enterprise pharma sponsors and 6,000+ research sites across 50+ countries.

Product overview

Inato is a unified AI-powered clinical trial platform that combines early planning, AI site selection, and AI patient pre-screening into one integrated system. The core Inato Platform connects 25 sponsors with 6,000+ research sites across 50+ countries. The platform consists of the Inato Marketplace (for site-investigator matching), AI Site Selection (leveraging verified data from 5,500+ sites for data-driven decisions), and AI Patient Pre-Screening (automating chart review with up to 90% time savings). Multiple case studies document outcomes including 181% enrollment achievement in asthma trials, 66% faster oncology enrollment, and significant time/cost savings through AI-powered workflows.

Differentiator

Problem solved

Functional benefit

Products and services

• Inato Platform AI-powered unified platform that connects pharmaceutical sponsors with clinical research sites for trial planning, site selection, and patient enrollment. Combines the Inato Marketplace, AI Site Selection, and AI Patient Pre-Screening into one integrated system for 25+ sponsors and 6,000+ research sites across 50+ countries.
• AI Site Selection AI-powered site selection capability enabling pharmaceutical sponsors to identify and match qualified, motivated research sites based on actual capabilities and patient access, using verified data from 5,500+ research sites.
• AI Patient Pre-Screening AI-powered patient pre-screening tool that automates chart review and pre-screening by evaluating patient records against protocol inclusion/exclusion criteria, providing rationale and source citations. Reduces chart review times by up to 90% with 95% accuracy.
• Inato Marketplace Two-sided data marketplace connecting pharmaceutical sponsors with clinical research sites, matching relevant investigators and sites for trials based on site capabilities and patient access data. Research sites can self-register to access trial opportunities; sponsors gain access to a database of 6,000+ research sites across 50+ countries.

Quantifiable outcome

• Up to 90% reduction in chart review times using AI patient pre-screening
• +8 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability8 records

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• RealTime eClinical SolutionscoreTechnology or Integration · 23 September 2025Strategic partnership announced September 23, 2025 to enhance site selection and trial enrollment. Combines RealTime-Devana's TrialAlign site data with Inato's patient access data, providing sponsors and CROs with unparalleled site performance insights. The partnership expands Inato's network by bringing 50+ large networks (2,000+ sites) onto the platform. Sites gain preferred access to Inato's AI patient pre-screening solution.
• CRIOcoreChannel Partner/ Reseller/ Distributor · 18 April 2025Inato joined CRIO's Partners Program, connecting CRIO-affiliated research sites with Inato's platform for trial discovery, site recommendations, and AI-powered patient pre-screening. Listed in CRIO's Partners Directory under Business Development and Feasibility category.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Deep 6 AI: AI-native clinical trial patient matching and site selection platform serving pharma sponsors. Closely comparable to Inato's AI Site Selection and AI Patient Pre-Screening products, with similar use of EHR-derived data for eligibility assessment.
• Mendel: AI platform that structures clinical and biomedical text to accelerate clinical trial recruitment. Competes with Inato on AI-driven patient cohort identification and chart review automation.
• Trial Library: Patient recruitment and clinical trial matching platform using AI and EHR data. Directly comparable to Inato on site and patient matching for pharma-sponsored trials.

Emerging players

• BEK Health: AI-powered clinical trial pre-screening platform focused on automating patient identification from EHR data. Competes with Inato's AI Patient Pre-Screening product with a narrower site-supply focus.
• Castor: Clinical trial platform providing EDC, eConsent, and decentralized trial capabilities for sponsors and sites. Overlaps with Inato on site-side trial enablement and patient data capture.

Broad incumbents

• IQVIA: Largest global CRO with extensive site network, real-world data assets, and AI-driven trial design and site selection offerings. Competes with Inato across the pharma sponsor workflow with broader service breadth.
• Labcorp Drug Development (Fortrea): Major global CRO (spun out from Labcorp) offering site selection, patient recruitment, and central lab services. Competes with Inato on sponsor-facing trial services with deeper enterprise relationships.
• Parexel: Global CRO providing site identification, patient recruitment, and clinical operations. Competes with Inato as a full-service sponsor partner with established biopharma relationships.
• Medidata (Dassault Systèmes): Leading clinical trial technology platform offering EDC, eCOA, randomization, and increasingly AI-driven trial operations. Overlaps with Inato on sponsor-side clinical operations and patient data workflows.
• Veeva Systems: Enterprise cloud software provider for life sciences, including Veeva Vault Clinical Suite used by sponsors and CROs. Competes with Inato on sponsor-facing trial planning and operations technology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/inatohealth

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Inato